Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialLancet Oncol 2022 Sep 13;[EPub Ahead of Print], AC Tree, P Ostler, H van der Voet, W Chu, A Loblaw, D Ford, S Tolan, S Jain, A Martin, J Staffurth, J Armstrong, P Camilleri, K Kancherla, J Frew, A Chan, IS Dayes, A Duffton, DH Brand, D Henderson, K Morrison, S Brown, J Pugh, S Burnett, M Mahmud, V Hinder, O Naismith, E Hall, N van As
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.